Levosimendán Altan

Levosimendan, the active ingredient in Levosimendán Altan, is a calcium sensitizer presented as an intravenous solution for intravenous use. It treats acute decompensated heart failure in adult patients by improving cardiac contractility and reducing vascular resistance.

GNH USA supplies Levosimendán Altan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levosimendan is used in the management of acute heart failure syndromes where rapid hemodynamic support is required.

Acute decompensated heart failure: improves cardiac output and relieves symptoms of congestion. Severe low‑output heart failure: enhances myocardial contractility to stabilize circulation. Post‑cardiac surgery low‑output syndrome: provides inotropic support during early postoperative recovery.

Levosimendan may be associated with several adverse reactions that clinicians monitor during therapy.

Common Side Effects: - Hypotension: reduction in systemic blood pressure. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Flushing: transient warmth and reddening of skin. - Arrhythmias: occasional premature beats. - Dizziness: related to blood pressure changes.

Serious or Rare Side Effects: - Severe hypotension: may require vasopressor support. - Ventricular tachycardia: potentially life‑threatening rhythm disturbance. - Myocardial ischemia: chest pain due to reduced coronary perfusion. - Anaphylactic reaction: rare hypersensitivity requiring emergency treatment. - Cardiac arrest: extremely rare but critical event. - Pulmonary edema: worsening fluid overload in susceptible patients.

Levosimendan requires careful patient assessment and monitoring before and during infusion.

Renal impairment: monitor renal function and adjust therapy as needed. Hepatic impairment: evaluate liver enzymes and consider dose modification. Hypotension: avoid rapid infusion rates and monitor blood pressure closely. Concurrent vasodilators: increased risk of excessive blood pressure fall. Arrhythmias: continuous ECG monitoring is recommended. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with other cardiovascular agents, influencing hemodynamic stability.

Major Interactions (Avoid): - Sodium nitroprusside: additive hypotensive effect. - Phosphodiesterase inhibitors: heightened risk of severe hypotension. - Strong CYP3A4 inhibitors: may increase plasma concentrations.

Moderate Interactions (Monitor Closely): - ACE inhibitors: monitor for synergistic blood pressure reduction. - Loop diuretics: watch for electrolyte disturbances. - Other inotropes (e.g., dobutamine): assess for excessive cardiac stimulation.